Growth hormone fragment peptide
hGH Fragment 176-191
hGH Fragment 176-191 is named in the 2026 WADA Prohibited List as an example of a growth hormone fragment; the app lists a half-life of 0.3 hours, and none of the sources read reports one.1
hGH Fragment 176-191 after one dose: 50% at ~0.3 h, 25% at 0.6 h, 12.5% at 0.9 h.
Drawn from the half-life in the app's model, ~0.3 h. The model's figures
- Compound
- hGH Fragment 176-191
- Symbol
- FRG
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 9
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
The app describes hGH Fragment 176-191 as the C-terminal fragment, amino acids 176 to 191, of human growth hormone, and lists it as a GH fragment. Habibullah and colleagues describe human growth hormone as "a 191-amino acid peptide hormone that is secreted by the anterior pituitary gland", so the fragment spans the last 16 residues of the molecule.2 Ng and Bornstein (American Journal of Physiology, 1978) studied synthetic peptides corresponding to amino acids 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191 of human growth hormone in normal rats.3
The names are not used consistently across the sources. Dominikowski and colleagues (Frontiers in Endocrinology, 2026) write that "AOD9604 is a synthetic C-terminal fragment of human GH, often described as hGH(177–191) with an additional N-terminal tyrosine", "hence sometimes labelled" with the name hGH 176–191.4 The app's notes describe AOD-9604 as a tyrosinated analogue that is structurally related to but distinct from hGH Fragment 176-191. Sections below therefore mark every AOD9604 result as an AOD9604 result and do not read it as a result for the fragment. The app grades the evidence as moderate; the sources read describe experiments in rats, in mice (for AOD9604), in cultured cells and in isolated adipose tissue from obese rodents and humans (for AOD-9401), and the Dominikowski review reports human studies of AOD9604, but no controlled trial of hGH Fragment 176-191 in people was identified in PubMed or ClinicalTrials.gov.
How it works
Wu and Ng (Biochemistry and Molecular Biology International, 1993, Monash University) reported that a synthetic hGH 177-191 peptide had antilipogenic activity "identical with that of the intact molecule of human growth hormone", and that there was "No significant lipolytic effect of hGH 177-191" by glycerol release from epididymal fat pads of treated rats.5 The authors conclude that "the main physiological effect of hGH in lipid metabolism is at the level of lipogenesis".5 Habibullah and colleagues state in their introduction that "A C-terminal hGH fragment 176–191 with a tyrosine to phenylalanine substitution at the last position has been reported to enhance lipid breakdown and fat utilization in mice".2 Heffernan and colleagues (International Journal of Obesity, 2001, Monash University) treated obese and lean mice with human growth hormone or AOD9604, a modified C-terminal fragment, and reported that "Both hGH and AOD significantly reduced body weight gain in obese mice", associated with "increased in vivo fat oxidation and increased plasma glycerol levels (an index of lipolysis)".6 The same report states that "AOD9604 does not compete for the hGH receptor and nor does it induce cell proliferation, unlike hGH".6 Ng and colleagues (Hormone Research, 2000) report that in obese Zucker rats an oral AOD9604 dose of 500 microg/kg body weight for 19 days reduced body weight gain, and that, unlike chronic intact hGH, it "showed no adverse effect on insulin sensitivity".7 A further Monash report (Heffernan and colleagues, American Journal of Physiology, 2000) studied a peptide coded AOD-9401, whose relation to hGH Fragment 176-191 its record does not state, and reported increased in vitro lipolytic activity and decreased lipogenic activity in isolated adipose tissue from obese rodents and humans.8 Ng and Bornstein reported a different effect for hGH 176-191 in rats: four of the six peptides tested, including 176-191, "produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin".3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.3 h
- Bioavailability
- 75%
- Typical dose
- 250–500 mcg/day
- Route
- SubQ
- Time to peak
- ~0.25 h
Sources in this part
The app lists a half-life of 0.3 hours (its notes give about 15 to 20 minutes), a bioavailability of 75%, a time to peak of 0.25 hours and a duration of 2 hours, for subcutaneous use in a one-compartment model. None of the sources read reports a measured half-life, bioavailability or time to peak for hGH Fragment 176-191 in any species. For AOD9604, the Dominikowski review's table gives "t½ not reported in human trials".4 Coutinho and colleagues (Journal of Sports Medicine and Physical Fitness, 2026) refer in general terms to "analytical challenges" in anti-doping "due to peptides' structural similarity to endogenous hormones and short half-lives", without giving a figure for this fragment.9
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.3 h (about 18 minutes) | No figure for hGH 176-191; the review lists AOD9604 with "t½ not reported in human trials"4 |
| Bioavailability | 75% | No figure for hGH 176-191 in the sources read |
| Time to peak | ~0.25 h | No figure for hGH 176-191 in the sources read |
| Duration | ~2 h | No figure for hGH 176-191 in the sources read |
| Route | SubQ | The review lists forum-reported subcutaneous use ("SC") of 250–500 µg/day for AOD9604 (hGH 176–191); the 1978 rat record does not state a route4,3 |
Human studies
No controlled trial of hGH Fragment 176-191 in people was identified in PubMed or ClinicalTrials.gov. A PubMed query for AOD9604 with "randomized placebo-controlled" also returned no records. The Dominikowski review, which groups AOD9604 and hGH 176–191 under one heading, states that human evidence is "limited and largely short-term".4 For AOD9604 as "an oral anti-obesity drug candidate", it reports a 24-week study (n=534, 502 randomized) in which "it failed to demonstrate a significant benefit on the primary weight-loss endpoint", and adds that conclusions "are based primarily on sponsor-reported phase 2 programme outcomes rather than peer-reviewed randomized efficacy trials".4 That is a result for AOD9604, secondhand through a review, and not a result for hGH Fragment 176-191. The studies below are the work on hGH 176-191 and closely related peptides that the searches returned; none of them is a human trial.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ng and Bornstein, American Journal of Physiology, 19783 | In vivo study of synthetic C-terminal peptides; the PubMed record names no funder3 | Normal rats; group sizes not given in the record3 | Single dose of 5 nmol/kg body weight for peptides containing 178-191; route not stated3 | hGH 176-191 was one of four peptides that produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin; hGH 179-191 and 180-191 were inert in the systems tested3 |
| Wu and Ng, Biochemistry and Molecular Biology International, 1993 (hGH 177-191)5 | Rat study of a synthetic 177-191 peptide; the PubMed record lists "Research Support, Non-U.S. Gov't" and names no funder5 | Rats; group sizes not given in the record5 | Dose and length not given in the record5 | Antilipogenic activity identical with intact hGH; no significant lipolytic effect by glycerol release from epididymal fat pads5 |
| Heffernan and colleagues, International Journal of Obesity, 2001 (AOD9604)6 | Controlled animal study against saline, plus receptor-binding and proliferation assays in transfected cells; the record lists "Research Support, Non-U.S. Gov't"6 | Obese (ob/ob) and lean C57BL/6J mice; group sizes not given in the record6 | hGH, AOD9604 or saline for 14 days by mini-osmotic pump; dose not given in the record6 | Both hGH and AOD9604 reduced body weight gain in obese mice; unlike hGH, AOD9604 did not induce hyperglycaemia or reduce insulin secretion6 |
| Habibullah and colleagues, Drug Design, Development and Therapy, 20222 | Docking simulations and an MTT viability assay of chitosan nanoparticles loaded with hGH 176–191 and doxorubicin, against doxorubicin-loaded nanoparticles and doxorubicin alone2 | Human MCF-7 breast cancer cells; no people2 | Cells treated for 48 hours with varied concentrations2 | Lower IC50 for the dual-loaded nanoparticles than for doxorubicin alone and doxorubicin-loaded nanoparticles; neither unloaded nor peptide-loaded nanoparticles showed substantial cytotoxicity2 |
Deeper analysis: Ng and Bornstein, rat study of hGH 176-191 (1978)
Ng and Bornstein (American Journal of Physiology, 1978) gave synthetic fragments of human growth hormone to normal rats and measured blood glucose, plasma insulin and insulin tolerance.3 Four peptides, including 176-191, produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin, while hGH 179-191 and 180-191 were "inert in the systems tested".3 The 176-191 sequence contains the 178-191 sequence, and the record reports that a single dose of 5 nmol/kg body weight of peptides containing 178-191 "significantly reduced insulin sensitivity".3 The authors state that "the biologically active peptides must not only have the minimum of the informational sequence but also that this must be in correct physical configuration".3 The PubMed record gives no group size, route, dose range, limitations section, funding statement or statement of author ties to a sponsor, so none can be reported here.
Deeper analysis: Wu and Ng, hGH 177-191 in rat fat tissue (1993)
Wu and Ng, of the Department of Biochemistry at Monash University, Clayton, Victoria, Australia, studied the 177-191 peptide in rats and measured antilipogenic activity and glycerol release from epididymal fat pads.5 The peptide's antilipogenic activity was "identical with that of the intact molecule of human growth hormone", while its lipolytic effect was not significant.5 The authors write that "The results support the suggestion that the functional domain responsible for the antilipogenic activity of hGH resides in the C-terminal region of the molecule".5 The PubMed record lists "Research Support, Non-U.S. Gov't" and gives no named funder, group size, dose, limitations or author ties to a sponsor.5
Deeper analysis: Heffernan and colleagues, AOD9604 in obese mice (2001)
Heffernan and colleagues, of the Department of Biochemistry and Molecular Biology at Monash University, studied AOD9604, which they call "a C-terminal fragment of hGH", in obese (ob/ob) and lean mice, with transfected cells used to test receptor binding and proliferation.6 They measured "Body weight, caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol" before and after 14 days of treatment.6 Both hGH and AOD9604 reduced body weight gain in obese mice; "Unlike hGH, however, AOD9604 did not induce hyperglycaemia or reduce insulin secretion".6 The authors conclude that AOD9604 "does not interact with the hGH receptor".6 The PubMed record lists "Research Support, Non-U.S. Gov't" and gives no named funder, group size, dose, limitations or author ties to a sponsor, and the work is on a modified fragment in mice, not on hGH 176-191 in people.6
Deeper analysis: Habibullah and colleagues, cell and docking study (2022)
Habibullah and colleagues (Drug Design, Development and Therapy, 2022) evaluated chitosan nanoparticles loaded with hGH fragment 176-191 plus doxorubicin, compared with chitosan loaded with doxorubicin alone.2 The methods were in silico docking against breast cancer receptors and a viability assay in human MCF-7 breast cancer cells, so the peptide was studied as a component of a drug carrier and not as a stand-alone agent.2 After 48 hours the dual-loaded nanoparticles gave an IC50 of 1.5 µg/mL against 1.85 µg/mL for doxorubicin alone and 1.7 µg/mL for doxorubicin-loaded chitosan, and "neither unloaded Chitosan nanoparticles nor peptide-loaded Chitosan nanoparticles demonstrated substantial cytotoxicity".2 Particle size and zeta potential were measured in triplicate (mean size 90.25 nm, zeta potential 31.7 mV), and the figure panels showing the single size and zeta potential distributions were labelled "(n = 1)".2 The authors list as limitations "its inability to presently conduct any morphological studies, entrapment efficiency, as well as in-vitro release study".2 The study states "This research was funded by the Deanship of Scientific Research, Jazan University, Jazan, Saudi Arabia", and its disclosure reads "The authors report no conflicts of interest in this work."2
Doses reported in studies and on labels
No prescribing label for hGH Fragment 176-191 was identified in DailyMed, so no label dose is available. The app's typical dose is 250 to 500 mcg/day by subcutaneous injection.
| Source | Compound | Dose and route | Duration, number and comparator |
|---|---|---|---|
| Ng and Bornstein 19783 | hGH 176-191 and related fragments | Single dose of 5 nmol/kg body weight (peptides containing 178-191); route not stated | One dose in normal rats; number not stated; 179-191 and 180-191 peptides inert in the systems tested |
| Heffernan and colleagues 20016 | AOD9604 | Dose not stated in the record; mini-osmotic pump | 14 days in obese and lean mice; saline comparator; number not stated |
| Ng and colleagues 20007 | AOD9604 | 500 microg/kg body weight, oral | Daily for 19 days in obese Zucker rats; control comparator; number not stated |
| Dominikowski review 2026, human studies of AOD96044 | AOD9604 (listed as hGH 176–191) | 25-400 µg IV infusion | Single administration; number and comparator not given in the review's table |
| Dominikowski review 2026, human studies of AOD96044 | AOD9604 | 1 mg PO once daily | 12 weeks, in obese patients; number and comparator not given in the review's table |
| Dominikowski review 2026, bodybuilding-related forums4 | AOD9604 (listed as hGH 176–191) | 250–500 µg/day SC in 2–3 injections | Typical cycle 8–12 weeks for body composition, as reported on forums; no comparator or number |
Side effects reported
Sources in this part
No adverse-event data for hGH Fragment 176-191 in people were identified in PubMed or ClinicalTrials.gov. For AOD9604, the Dominikowski review's table states "Generally well tolerated; mild/transient headache, fatigue, injection reactions; no significant alterations in glucose tolerance or IGF−1 observed; theoretical concerns regarding efficacy and long-term metabolic effects remain due to limited human trial data".4 The same table adds "No long term safety data available".4 Coutinho and colleagues write in general terms about peptides used in sport, a group that includes "synthetic fragments (e.g., Frag 176-191, KPV)", that "Emerging data highlight potential risks: cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability".9 They add that "The largely unregulated supply chain exacerbates these dangers, as products are often mislabeled or contaminated".9 These statements concern peptides as a group, not measured events with hGH 176-191.
Bloodwork and markers
Sources in this part
The app lists no health markers to monitor for hGH Fragment 176-191. In the animal work above, the markers measured were blood glucose, plasma insulin and insulin tolerance in rats (Ng and Bornstein 1978), and body weight, caloric intake, energy expenditure, fat and glucose oxidation, plasma glucose, insulin and glycerol in mice given AOD9604 (Heffernan and colleagues 2001).3,6 The glucose findings differ between the two: the rat record reports a rise in blood glucose and insulin with hGH 176-191, and the mouse record reports that AOD9604 "did not induce hyperglycaemia".3,6 The two used different peptides, species and designs, so neither result is read as a contradiction of the other.
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List, which "shall come into effect on 1 January 2026", names hGH 176-191 in section S2.2.3, "Growth hormone (GH), its analogues and fragments including, but not limited to", with the example "growth hormone fragments, e.g. AOD-9604 and hGH 176-191".1 The S2 class is listed under substances "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".1 The list states that "All prohibited substances in this class are non-Specified Substances".1 The Dominikowski review states that "AOD9604 is not approved by major regulatory agencies for any indication".4 No drug label for hGH Fragment 176-191 was identified in DailyMed, and no regulator approval document was identified in the searches run. Coutinho and colleagues write that the World Anti-Doping Agency has "responded by expanding detection technologies, yet analytical challenges remain".9
What is not known
Sources in this part
- No half-life, bioavailability, time to peak or duration measured for hGH Fragment 176-191 was identified, so the app's figures of 0.3 hours, 75%, 0.25 hours and 2 hours have no measured figure from the sources beside them here.
- No controlled trial of the fragment in people, and so no efficacy or safety figure for it, was identified in PubMed or ClinicalTrials.gov.
- The glucose findings differ between the rat record (a rise in blood glucose and insulin with hGH 176-191) and the mouse record (AOD9604 did not induce hyperglycaemia), but the peptides, species and designs differ, so the sources read do not settle whether the 176-191 sequence acts on glucose.3,6
- The sources use "hGH 176-191", "177-191" and "AOD9604" with overlapping meanings, so which results belong to which peptide is not settled by the sources read.4
- The funders of the 1978, 1993, 2000 (Ng and Heffernan) and 2001 studies are not named in their PubMed records; the Wu and Ng 1993, Heffernan 2000 and Heffernan 2001 records list "Research Support, Non-U.S. Gov't", and the Ng and Bornstein 1978 and Ng 2000 records state no funding.
Frequently asked questions
What is the half-life of hGH Fragment 176-191?
The app lists a half-life of 0.3 hours, about 18 minutes, and none of the sources read gives a measured figure for the fragment. For AOD9604 the Dominikowski review gives "t½ not reported in human trials".4
Is hGH Fragment 176-191 banned by WADA?
What is hGH Fragment 176-191?
The app describes it as the C-terminal fragment, amino acids 176 to 191, of human growth hormone. Ng and Bornstein studied a synthetic peptide of that sequence in rats in 1978.3
Is hGH Fragment 176-191 the same as AOD-9604?
The app's notes describe AOD-9604 as a tyrosinated analogue that is structurally related to but distinct from hGH Fragment 176-191. The Dominikowski review describes AOD9604 as "often described as hGH(177–191) with an additional N-terminal tyrosine", "hence sometimes labelled" hGH 176–191.4
Has hGH Fragment 176-191 been tested in people?
No controlled trial of it in people was identified in PubMed or ClinicalTrials.gov. For AOD9604 the review reports a 24-week study (n=534, 502 randomized) in which "it failed to demonstrate a significant benefit on the primary weight-loss endpoint".4
Does hGH Fragment 176-191 raise blood sugar?
In normal rats, Ng and Bornstein reported that hGH 176-191 was among four peptides that produced "a short-lived rise in blood glucose and a more sustained rise in plasma insulin".3 No human glucose data for the fragment were identified.
Does hGH Fragment 176-191 break down fat?
Is hGH Fragment 176-191 approved as a drug?
No drug label for it was identified in DailyMed, and the Dominikowski review states that "AOD9604 is not approved by major regulatory agencies for any indication".4
What dose range does the app list for hGH Fragment 176-191?
The app lists 250 to 500 mcg/day by subcutaneous injection. The Dominikowski review reports the same range, "250–500 µg/day SC in 2–3 injections", from bodybuilding-related forums, for AOD9604.4
Guides, tools and comparisons
References
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
- Habibullah MM, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther 2022. PMID 35783198
- Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol 1978. PMID 645904
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMID 42395176
- Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int 1993. PMID 8358331
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 2001. PMID 11673763
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000. PMID 11146367
- Heffernan MA, et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab 2000. PMID 10950816
- Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness 2026. PMID 41880199